Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Eagle Pharmaceuticals
Deal Size : $182.4 million
Deal Type : Acquisition
Details : With the acquisition, addition of the two products expands the presence in acute care space, BARHEMSYS® (amisulpride for injection) and BYFAVO® (remimazolam for injection) join Eagle portfolio.
Product Name : Barhemsys
Product Type : Other Small Molecule
Upfront Cash : $78.5 million
September 06, 2022
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Eagle Pharmaceuticals
Deal Size : $182.4 million
Deal Type : Acquisition
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Eagle Pharmaceuticals
Deal Size : $182.4 million
Deal Type : Acquisition
Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc
Details : Opportunity for Eagle’s highly skilled hospital-based salesforce to integrate and promote BYFAVO and BARHEMSYS and to leverage longstanding relationships to realize the full potential of these assets.
Product Name : Barhemsys
Product Type : Other Small Molecule
Upfront Cash : $78.5 million
March 28, 2022
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Eagle Pharmaceuticals
Deal Size : $182.4 million
Deal Type : Acquisition
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Barhemsys® is an intravenous formulation of amisulpride, a selective dopamine antagonist. It is approved in the US for treatment and prophylaxis of PONV, alone and in combination with other antiemetics.
Product Name : Barhemsys
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2021
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : $23.5 million
Deal Type : Financing
Details : The net proceeds of the Placing are intended to be used To meet its sales force and marketing costs relating to BARHEMSYS® and BYFAVO™ including brand development and engagement with key opinion leaders, healthcare professionals and medical conference...
Product Name : Barhemsys
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 18, 2021
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : $23.5 million
Deal Type : Financing
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BYFAVO is the second Acacia Pharma product approved and launched in the US in the last year and extends its portfolio of new products targeting unmet needs in anesthesia.
Product Name : Byfavo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 28, 2021
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Cosmo Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Financing
Details : The Company plans to deploy this capital to support its ongoing US launches of BARHEMSYS® (amisulpride injection) for postoperative nausea & vomiting and BYFAVO™ (remimazolam for injection) for procedural sedation.
Product Name : Barhemsys
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 10, 2020
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Cosmo Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Cosmo Pharmaceuticals
Deal Size : $143.2 million
Deal Type : Licensing Agreement
Issue of Equity on Share Subscription and Licensing agreement With Cosmo Pharmaceuticals
Details : Acacia Pharma will be responsible for the marketing and distribution of ByFavo in the US in the context of its equity-for-product strategy.
Product Name : Byfavo
Product Type : Other Small Molecule
Upfront Cash : $11.1 million
September 01, 2020
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Cosmo Pharmaceuticals
Deal Size : $143.2 million
Deal Type : Licensing Agreement
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BARHEMSYS® (amisulpride injection) has been launched and is now commercially available in the US for order and delivery to customers through major wholesalers and specialty distributors.
Product Name : Barhemsys
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2020
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Acacia Pharma Announces BYFAVO its Newly Approved Product for Procedural Sedation
Details : US DEA has designated its procedural sedative BYFAVO™ (remimazolam injection) as a Schedule IV medicine. This designation is the schedule for drugs with a low potential for abuse and low risk of dependence and is consistent with that granted to many ot...
Product Name : Byfavo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2020
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable